Histopathology and Molecular Pathology of Vitiligo

Vitiligo is a common skin disorder that manifests as whitish macules. There is no special geographic or sex predilection. Vitiligo is a multifactorial disorder. The various theories proposed include neutral theory, autoimmune theory, zincα2-glycoprotein theory, viral infection, intrinsic theory and melanocytorrhagy theory. However, the currently favored opinion is that there is a convergence of various theories known as the convergence theory. The basic defect is the absence of functional melanocytes from the epidermal melanin unit. This absence can be demonstrated by using special stains like Fontana-Masson, immunohistochemistry like HMB-45 and Melan-A and electron microscopy. Margins of lesions especially early lesions show inflammatory cells principally CD4+ and CD8+ T cells. The cornerstone of management in vitiligo is correct categorization of a case into stable and unstable vitiligo. This distinction is based mainly on clinical criteria. It is recommended that while evaluating biopsies, histopathological examination should be primarily concentrated on evaluating five histopathological variables—spongiosis, epidermal lymphocytes, basal cell vacuolation, dermal lymphocytes and melanophages. These parameters are then scored using a scoring system, and the recommended diagnoses based on these scores are given. Adoption of a systematic reporting system brings more consistency and objectivity in the diagnosis.

[1]  A. Yadav,et al.  Clinicopathologic Analysis of Stable and Unstable Vitiligo: A Study of 66 Cases , 2016, The American Journal of dermatopathology.

[2]  M. Picardo,et al.  On the pathophysiology of vitiligo: possible treatment options. , 2012, Indian journal of dermatology, venereology and leprology.

[3]  Meaghan Daly,et al.  Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. , 2011, Journal of the American Academy of Dermatology.

[4]  N. Bagherani,et al.  HYPOTHESIS: ZINC CAN BE EFFECTIVE IN TREATMENT OF VITILIGO , 2011, Indian journal of dermatology.

[5]  N. Bagherani,et al.  Vitiligo: A review of the published work , 2011, The Journal of dermatology.

[6]  O. Shaker,et al.  Role of interleukin‐17 in the pathogenesis of vitiligo , 2011, Clinical and experimental dermatology.

[7]  A. Ökten,et al.  Relevance of autoimmune thyroiditis in children and adolescents with vitiligo , 2011, International journal of dermatology.

[8]  D. Gawkrodger,et al.  Autoantibodies against tyrosine hydroxylase in patients with non‐segmental (generalised) vitiligo , 2011, Experimental dermatology.

[9]  L. Naldi,et al.  Vitiligo and autoimmunity: an epidemiological study in a representative sample of young Italian males , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  C. Melief,et al.  Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. , 2009, The Journal of investigative dermatology.

[11]  G. Lauzon,et al.  Analysis of interleukin‐10 levels in lesions of vitiligo following treatment with topical tacrolimus , 2009, The British journal of dermatology.

[12]  H. Attia,et al.  Antioxidant enzymes and lipid peroxidation at the tissue level in patients with stable and active vitiligo , 2009, International journal of dermatology.

[13]  Rebat M Halder,et al.  Vitiligo update. , 2009, Seminars in cutaneous medicine and surgery.

[14]  N. J. Gibbons,et al.  Presence of epidermal allantoin further supports oxidative stress in vitiligo , 2008, Experimental dermatology.

[15]  Eun-So Lee,et al.  Histopathologic Features in Vitiligo , 2008, The American Journal of dermatopathology.

[16]  E. Dellambra,et al.  Keratinocyte cultures from involved skin in vitiligo patients show an impaired in vitro behaviour. , 2007, Pigment cell research.

[17]  L. Manolache,et al.  Stress in patients with alopecia areata and vitiligo , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  A. Traoré,et al.  Vitiligo sur peau noire associé au VIH et repigmentation lors du traitement antirétroviral , 2007 .

[19]  R. Mıstık,et al.  Is there any relation between vitiligo and cytomegalovirus? , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[20]  A. Taïeb,et al.  [Vitiligo in a black patient associated with HIV infection and repigmentation under antiretroviral therapy]. , 2007, Annales de dermatologie et de venereologie.

[21]  Wei Zhou,et al.  MHC haplotypic association in Chinese Han patients with vitiligo , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

[22]  Turki Hamida,et al.  A comparative study of oxidant–antioxidant status in stable and active vitiligo patients , 2006, Archives of Dermatological Research.

[23]  R. Yehuda,et al.  Plasma Neuropeptide Y Concentrations in Combat Exposed Veterans: Relationship to Trauma Exposure, Recovery from PTSD, and Coping , 2006, Biological Psychiatry.

[24]  R. Robati,et al.  Anti-thyroid peroxidase antibody and vitiligo: a controlled study , 2006, BMC dermatology.

[25]  M. Namazi Phenytoin as a novel anti-vitiligo weapon , 2005, Journal of autoimmune diseases.

[26]  M. Herlyn,et al.  Normal human melanocyte homeostasis as a paradigm for understanding melanoma. , 2005, The journal of investigative dermatology. Symposium proceedings.

[27]  Nan-Hyung Kim,et al.  Less keratinocyte-derived factors related to more keratinocyte apoptosis in depigmented than normally pigmented suction-blistered epidermis may cause passive melanocyte death in vitiligo. , 2005, The Journal of investigative dermatology.

[28]  Y. Youm,et al.  Keratinocytes in the depigmented epidermis of vitiligo are more vulnerable to trauma (suction) than keratinocytes in the normally pigmented epidermis, resulting in their apoptosis , 2004, The British journal of dermatology.

[29]  B. Barutcuoglu,et al.  Is There Any Relationship Between Hepatitis C Virus and Vitiligo? , 2004, Journal of clinical gastroenterology.

[30]  R. Morris,et al.  Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. , 2004, Journal of the American Academy of Dermatology.

[31]  N. J. Gibbons,et al.  Perturbed 6-tetrahydrobiopterin recycling via decreased dihydropteridine reductase in vitiligo: more evidence for H2O2 stress. , 2004, The Journal of investigative dermatology.

[32]  A. Taïeb,et al.  A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? , 2003, Pigment cell research.

[33]  F. Benvenuto,et al.  Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. , 2003, The Journal of investigative dermatology.

[34]  R. Spritz,et al.  Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. , 2003, Pigment cell research.

[35]  G. Ogg,et al.  Immunopolarization of CD4+ and CD8+ T Cells to Type-1–Like is Associated with Melanocyte Loss in Human Vitiligo , 2003, Laboratory Investigation.

[36]  L. Hale Zinc α-2-glycoprotein Regulates Melanin Production by Normal and Malignant Melanocytes , 2002 .

[37]  L. Hale Zinc alpha-2-glycoprotein regulates melanin production by normal and malignant melanocytes. , 2002, The Journal of investigative dermatology.

[38]  W. Westerhof,et al.  Local Immune Response in Skin of Generalized Vitiligo Patients , 2000, Laboratory Investigation.

[39]  C. Yu,et al.  Cutaneous blood flow and adrenoceptor response increase in segmental-type vitiligo lesions. , 2000, Journal of dermatological science.

[40]  S. Handa,et al.  Vitiligo: Clinical Findings in 1436 Patients , 1999, The Journal of dermatology.

[41]  I. L. Le Poole,et al.  Microscopic changes in vitiligo. , 1997, Clinics in dermatology.

[42]  W. Westerhof,et al.  Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. , 1996, The American journal of pathology.

[43]  D. Gawkrodger,et al.  Neuropeptide and neuronal marker studies in vitiligo , 1994, The British journal of dermatology.

[44]  W. Westerhof,et al.  Review of the etiopathomechanism of vitiligo: A convergence theory , 1993, Experimental dermatology.

[45]  W. Westerhof,et al.  Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. , 1993, The Journal of investigative dermatology.

[46]  J. Bystryn,et al.  Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. , 1991, The Journal of investigative dermatology.

[47]  E. Medrano,et al.  Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. , 1991, The Journal of investigative dermatology.

[48]  R. Koranne,et al.  Vitiligo , 1988 .

[49]  K. Sharquie Vitiligo , 1984 .

[50]  J. Nordlund,et al.  Vitiligo: It Is Important , 1982 .

[51]  J. Nordlund,et al.  Vitiligo. What is it? Is it important? , 1978, JAMA.

[52]  A. Lerner Part V: Clinical Applications of Psoralens, and Related Materials: Vitiligo11From the Section of Dermatology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut. , 1959 .